Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participants

Zhaoyang Li(Guiyang Medical University), Leman Yel(Children's Hospital of Philadelphia), Noor M. Khaskhely(Takeda (United States)), Kimberly Duff(Takeda (United States)), Juan Carlos Rondón(Clinical Pharmacology of Miami), Dirk Lindner(Takeda (United States)), András Nagy(University of Szeged), Enrique García(Takeda (United States)), Hakan Ay(Institute of Neuroimmunology of the Slovak Academy of Sciences)
Clinical Immunology
May 1, 2023
10.1016/j.clim.2023.109529
Cited by 1

Related Papers

A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms
|Cardiovascular Drugs and Therapy|2024|38
Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference
|Journal of Clinical Immunology|2021|28
Chemical Constituents and Hypoglycemic Mechanisms of Dendrobium nobile in Treatment of Type 2 Diabetic Rats by UPLC-ESI-Q-Orbitrap, Network Pharmacology and In Vivo Experimental Verification
|Molecules|2023|23
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
|Immunotherapy|2024|5
Vitamin D and breast cancer
|Orvosi Hetilap|2014|4